Drug interaction potential of resveratrol

References

• Almeida, L., Vaz-da-Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A. I., et al. (2009). Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53(Suppl 1):S7–S15.
   PubMed Web of Science ®Google Scholar
• Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M. C., Obrador, E., et al. (2002). Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33:387–398.
   PubMed Web of Science ®Google Scholar
• Bailey, D. G., Malcolm, J., Arnold, O., Spence, J. D. (1998). Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101–110.
   PubMed Web of Science ®Google Scholar
• Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342.
   PubMed Web of Science ®Google Scholar
• Bebia, Z., Buch, S. C., Wilson, J. W., Frye, R. F., Romkes, M., Cecchetti, A., et al. (2004). Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76:618–627.
   PubMed Web of Science ®Google Scholar
• Blanchard, N., Richert, L., Coassolo, P., Lavé, T. (2004). Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50, and inhibitor concentration. Curr Drug Metab 5:147–156.
   PubMed Web of Science ®Google Scholar
• Bogaards, J. J., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., van Bladeren, P. J., et al. (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey, and man. Xenobiotica 30:1131–1152.
   PubMed Web of Science ®Google Scholar
• Boocock, D. J., Faust, G. E. S., Patel, K. R., Schinas, A. M., Brown, V. A., Ducharme, M. P., et al. (2007). Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246–1252.
   PubMed Web of Science ®Google Scholar
• Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., et al. (2010). Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70:9003–9011.
   PubMed Web of Science ®Google Scholar
• Calabrese, E. J., Mattson, M. P., Calabrese, V. (2010). Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exp Toxicol 29:980–1015.
   PubMed Web of Science ®Google Scholar
• Canistro, D., Bonamassa, B., Pozzetti, L., Sapone, A., Abdel-Rahman, S. Z., Biagi, G. L., et al. (2009). Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice. Food Chem Toxicol 47:454–461.
   PubMed Web of Science ®Google Scholar
• Casper, R. F., Quesne, M., Rogers, I. M., Shirota, T., Jolivet, A., Milgrom, E., et al. (1999). Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56:784–790.
   PubMed Web of Science ®Google Scholar
• Chan, W. K., Delucchi, A. B. (2000). Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 67:3103–3112.
   PubMed Web of Science ®Google Scholar
• Chan, W. K., Nguyen, L. T., Miller, V. P., Harris, R. Z. (1998). Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 62:PL135–PL142.
   PubMed Web of Science ®Google Scholar
• Chang, T. K., Chen, J., Lee, W. B. (2001). Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 299:874–882.
   PubMed Web of Science ®Google Scholar
• Chang, T. K., Yeung, R. K. (2001). Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can J Physiol Pharmacol 79:220–226.
   PubMed Web of Science ®Google Scholar
• Choi, J.-S., Choi, B.-C., Kang, K. W. (2009). Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie 64:49–52.
   PubMed Web of Science ®Google Scholar
• Chow, H.-H. S., Garland, L. L., Hsu, C.-H., Vining, D. R., Chew, W. M., Miller, J. A., et al. (2010). Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168–1175.
   PubMed Web of Science ®Google Scholar
• Chun, Y. J., Kim, M. Y., Guengerich, F. P. (1999). Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262:20–24.
   PubMed Web of Science ®Google Scholar
• Ciolino, H. P., Yeh, G. C. (1999). Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56:760–767.
   PubMed Web of Science ®Google Scholar
• Crowell, J. A., Korytko, P. J., Morrissey, R. L., Booth, T. D., Levine, B. S. (2004a). Resveratrol-associated renal toxicity. Toxicol Sci 82:614–619.
   PubMed Web of Science ®Google Scholar
• Crowell, J. A., Levine, B. S., McCormick, D. L. (2004b). Resveratrol: drug development for cancer prevention (abstract no. 356) In: Abstracts of the 10th International Congress of Toxicology, July 11–15, 2004, Tampere, Finland. Toxicol Appl Pharmacol 197:218.
   Google Scholar
• Delcò, F., Tchambaz, L., Schlienger, R., Drewe, J., Krähenbühl, S. (2005). Dose adjustment in patients with liver disease. Drug Saf 28:529–545.
   PubMed Web of Science ®Google Scholar
• Edwards, J. A., Beck, M., Riegger, C., Bausch, J. (2011). Safety of resveratrol with examples for high purity, trans-resveratrol, resVida®. Ann N Y Acad Sci 1215:131–137.
   PubMed Web of Science ®Google Scholar
• Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., Baillie, T. A. (2004). Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3–16.
   PubMed Web of Science ®Google Scholar
• Galetin, A., Gertz, M., Houston, J. B. (2010). Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 25:28–47.
   PubMed Web of Science ®Google Scholar
• Gill, M. T., Bajaj, R., Chang, C. J., Nichols, D. E., McLaughlin, J. L. (1987). 3,3′,5′-Tri-O-methylpiceatannol and 4,3′,5′-tri-O-methylpiceatannol: improvements over piceatannol in bioactivity. J Nat Prod 50:36–40.
   PubMed Web of Science ®Google Scholar
• Goldberg, D. M., Yan, J., Soleas, G. J. (2003). Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79–87.
   PubMed Web of Science ®Google Scholar
• Goosen, T. C., Cillié, D., Bailey, D. G., Yu, C., He, K., Hollenberg, P. F., et al. (2004). Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther 76:607–617.
   PubMed Web of Science ®Google Scholar
• Gu, J., Wang, C., Fan, H., Ding, H., Xie, X., Xu, Y., et al. (2006). Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats. J Cardiovasc Pharmacol 47:711–721.
   PubMed Web of Science ®Google Scholar
• Gusman, J., Malonne, H., Atassi, G. (2001). A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22:1111–1117.
   PubMed Web of Science ®Google Scholar
• He, K., Iyer, K. R., Hayes, R. N., Sinz, M. W., Woolf, T. F., Hollenberg, P. F. (1998). Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252–259.
   PubMed Web of Science ®Google Scholar
• Hebbar, V., Shen, G., Hu, R., Kim, B.-R., Chen, C., Korytko, P. J., et al. (2005). Toxicogenomics of resveratrol in rat liver. Life Sci 76:2299–2314.
   PubMed Web of Science ®Google Scholar
• Hong, S.-P., Choi, D.-H., Choi, J.-S. (2008). Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. Cardiovasc Ther 26:269–275.
   PubMed Web of Science ®Google Scholar
• Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., et al. (2011). Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases—safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 4:1419–1425.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg, M. (2004). Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Arch Pharmacol 369:89–104.
   Google Scholar
• Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220.
   PubMed Web of Science ®Google Scholar
• Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A., et al. (2010). Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 91:1590–1597.
   PubMed Web of Science ®Google Scholar
• Kondratyuk, T. P., Park, E.-J., Marler, L. E., Ahn, S., Yuan, Y., Choi, Y., et al. (2011). Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol Nutr Food Res 55:1249–1265.
   PubMed Web of Science ®Google Scholar
• Kopp, P. (1998). Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the “French paradox”? Eur J Endocrinol 138:619–620.
   PubMed Web of Science ®Google Scholar
• Kupferschmidt, H. H., Ha, H. R., Ziegler, W. H., Meier, P. J., Krähenbühl, S. (1995). Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58:20–28.
   PubMed Web of Science ®Google Scholar
• Lilja, J. J., Kivistö, K. T., Backman, J. T., Lamberg, T. S., Neuvonen, P. J. (1998). Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 64:655–660.
   PubMed Web of Science ®Google Scholar
• Marier, J.-F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.-P., Ducharme, M. P. (2002). Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302:369–373.
   PubMed Web of Science ®Google Scholar
• Martignoni, M., Groothuis, G. M., de Kanter, R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–894.
   PubMed Web of Science ®Google Scholar
• McLaughlin, L. A., Dickmann, L. J., Wolf, C. R., Henderson, C. J. (2008). Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos 36:1322–1331.
   PubMed Web of Science ®Google Scholar
• Meyer, U. A. (2000). Pharmacogenetics and adverse drug reactions. Lancet 356:1667–1671.
   PubMed Web of Science ®Google Scholar
• Mikstacka, R., Gnojkowski, J., Baer-Dubowska, W. (2002). Effect of natural phenols on the catalytic activity of cytochrome P450 2E1. Acta Biochim Pol 49:917–925.
   PubMed Web of Science ®Google Scholar
• Mugford, C. A., Kedderis, G. L. (1998). Sex-dependent metabolism of xenobiotics. Drug Metab Rev 30:441–498.
   PubMed Web of Science ®Google Scholar
• Nebert, D. W., Roe, A. L., Dieter, M. Z., Solis, W. A., Yang, Y., Dalton, T. P. (2000). Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 59:65–85.
   PubMed Web of Science ®Google Scholar
• Nunes, T., Almeida, L., Rocha, J.-F., Falcão, A., Fernandes-Lopes, C., Loureiro, A. I., et al. (2009). Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 49:1477–1482.
   PubMed Web of Science ®Google Scholar
• Offman, E. M., Freeman, D. J., Dresser, G. K., Munoz, C., Bend, J. R., Bailey, D. G. (2001). Red wine-cisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther 70:17–23.
   PubMed Web of Science ®Google Scholar
• Ozdemir, M., Aktan, Y., Boydag, B. S., Cingi, M. I., Musmul, A. (1998). Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 23:55–59.
   PubMed Web of Science ®Google Scholar
• Patel, K. R., Scott, E., Brown, V. A., Gescher, A. J., Steward, W. P., Brown, K. (2011). Clinical trials of resveratrol. Ann N Y Acad Sci 1215:161–169.
   PubMed Web of Science ®Google Scholar
• Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L., Price, N. L., Labinskyy, N., et al. (2008). Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8:157–168.
   PubMed Web of Science ®Google Scholar
• Piver, B., Berthou, F., Dreano, Y., Lucas, D. (2001). Inhibition of CYP3A, CYP1A, and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 125:83–91.
   PubMed Web of Science ®Google Scholar
• Piver, B., Berthou, F., Dreano, Y., Lucas, D. (2003). Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci 73:1199–1213.
   PubMed Web of Science ®Google Scholar
• Piver B, Fer M, Vitrac X, Merillon J-M, Dreano Y, Berthou F, LucasD. (2004). Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol 68:773–782.
   PubMed Web of Science ®Google Scholar
• Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler, P. C., Ijaz, T., et al. (2002). The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86:774–778.
   PubMed Web of Science ®Google Scholar
• Raucy, J. L. (2003). Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31:533–539.
   PubMed Web of Science ®Google Scholar
• Regev-Shoshani, G., Shoseyov, O., Kerem, Z. (2004). Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4. Biochem Biophys Res Commun 323:668–673.
   PubMed Web of Science ®Google Scholar
• Revel, A., Raanani, H., Younglai, E., Xu, J., Rogers, I., Han, R., et al. (2003). Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 23:255–261.
   PubMed Web of Science ®Google Scholar
• Sale, S., Verschoyle, R. D., Boocock, D., Jones, D. J. L., Wilsher, N., Ruparelia, K. C., et al. (2004). Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br J Cancer 90:736–744.
   PubMed Web of Science ®Google Scholar
• Sandhu, M. S., Dunger, D. B., Giovannucci, E. L. (2002). Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94:972–980.
   PubMed Web of Science ®Google Scholar
• Sergent, T., Dupont, I., Van der Heiden, E., Scippo, M.-L., Pussemier, L., Larondelle, Y., et al. (2009). CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal Caco-2 cells. Toxicol Lett 191:216–222.
   PubMed Web of Science ®Google Scholar
• Sirtris, GlaxoSmithKline. (2011). A clinical study to assess the safety and activity of SRT501 alone or in combination with bortezomib in patients with multiple myeloma. In: ClinicalTrials.gov [Online]. Bethesda (MD): National Library of Medicine (US). Available at: http://clinicaltrials.gov/show/NCT00920556 NLM Identifier: NCT00920556. Accessed on December 2, 2011.
   Google Scholar
• Smoliga, J. M., Baur, J. A., Hausenblas, H. A. (2011). Resveratrol and health—a comprehensive review of human clinical trials. Mol Nutr Food Res 55:1129–1141.
   PubMed Web of Science ®Google Scholar
• Snyder, S. A., Gollner, A., Chiriac, M. I. (2011). Regioselective reactions for programmable resveratrol oligomer synthesis. Nature 474:461–466.
   PubMed Web of Science ®Google Scholar
• Soleas, G. J., Yan, J., Goldberg, D. M. (2001). Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Biomed Sci Appl 757:161–172.
   PubMed Web of Science ®Google Scholar
• Stervbo, U., Vang, O., Bonnesen, C. (2007). A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem 101:449–457.
   Web of Science ®Google Scholar
• Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., et al. (2011). Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14:612–622.
   PubMed Web of Science ®Google Scholar
• Todesco, L., Bodmer, M., Vonwil, K., Häussinger, D., Krähenbühl, S. (2009). Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2. Chem Biol Interact 180:472–477.
   PubMed Web of Science ®Google Scholar
• Trusov, N. V., Guseva, G. V., Aksenov, I. V., Avren’eva, L. I., Kravchenko, L. V., Tutelyan, V. A. (2010). Effects of combined treatment with resveratrol and indole-3-carbinol. Bull Exp Biol Med 149:213–218.
   PubMed Web of Science ®Google Scholar
• Tsunoda, S. M., Harris, R. Z., ChristiansU., Velez, R. L., Freeman, R. B., Benet, L. Z., et al. (2001). Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 70:462–467.
   PubMed Web of Science ®Google Scholar
• U.S. FDA (2005). Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. [Online]. Silver Spring, Maryland, USA: FDA. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. Accessed on 06 December 2011.
   Google Scholar
• Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., et al. (2011). What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE 6:e19881.
   Web of Science ®Google Scholar
• Weinshilboum, R. (2003). Inheritance and drug response. N Engl J Med 348:529–537.
   PubMed Web of Science ®Google Scholar
• Williams, L. D., Burdock, G. A., Edwards, J. A., Beck, M., Bausch, J. (2009). Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 47:2170–2182.
   PubMed Web of Science ®Google Scholar
• Wong, R. H. X., Howe, P. R. C., Buckley, J. D., Coates, A. M., Kunz, I., Berry, N. M. (2011). Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 21:851–856.
   PubMed Web of Science ®Google Scholar
• Yang, C. S., Pan, E. (2012). The effects of green tea polyphenols on drug metabolism. Expert Opin Drug Metab Toxicology 8:677–689.
   PubMed Web of Science ®Google Scholar
• Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., van Breemen, R. B. (2003). Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom 17:307–313.
   PubMed Web of Science ®Google Scholar
• Yu, W., Fu, Y.-C., Wang, W. (2011). Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 113:752–759.
   Web of Science ®Google Scholar
• Zhang, L., Zhang, Y. D., Strong, J. M., Reynolds, K. S., Huang, S.-M. (2008). A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709–724.
   PubMed Web of Science ®Google Scholar
• Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304.
   PubMed Web of Science ®Google Scholar
• Zhou, S.-F., Liu, J.-P., Chowbay, B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295.
   PubMed Web of Science ®Google Scholar